Our expertise resides in:

• Scientific support for cancer therapy development strategy
• First-in-man trials
• Clinical optimization of single agent and combination therapies
• Exploration of treatments for targeted populations with unmet needs
• Management of clinical trials necessary for successful registration
• Implementation of compassionate–use program

We have assisted various companies in early product development through MTD definition, PK analysis and recommendation of Phase II/III strategies, and have solid experience in performing international Phase I, II and Phase III studies for registration purposes.

NUVISAN Oncology is using the most stringent standards and can therefore deliver GCP-compliant operations with optimised timelines and quality.